Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic nonesmall cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02

被引：12

作者：

Li, B. T. ^{[1
]}

Planchard, D. ^{[2
]}

Goto, K. ^{[3
]}

Smit, E. F. ^{[4
]}

De langen, J. ^{[5
]}

Goto, Y. ^{[6
]}

Ninomiya, K. ^{[7
]}

Kubo, T. ^{[8
]}

Perol, M. ^{[9
]}

Felip, E. ^{[10
]}

Hayashi, H. ^{[11
]}

Nakagawa, K. ^{[11
]}

Shimizu, J. ^{[12
]}

Nagasaka, M. ^{[13
]}

Pereira, K. M. C. ^{[14
]}

Taguchi, A. ^{[15
]}

Ali, A. ^{[16
]}

Karnoub, M.

Yonemochi, R. ^{[14
]}

Janne, P. A. ^{[17
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA

[2] Gustave Roussy, Med Oncol, Villejuif, France

[3] Natl Canc Ctr Hosp East, Dept Thorac Oncol, Kashiwa, Chiba, Japan

[4] LUMC Leiden Univ, Dept Pulm Dis, Med Ctr, Leiden, Netherlands

[5] Netherlands Canc Inst, Dept Thorac Oncol, Amsterdam, Netherlands

[6] Natl Canc Ctr, Thorac Oncol, Tokyo, Japan

[7] Okayama Univ Hosp, Ctr Comprehens Genom Med, Okayama, Japan

[8] Okayama Univ Hosp, Ctr Clin Oncol, Okayama, Japan

[9] Leon Berard Canc Ctr, Med Oncol, Lyon, France

[10] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain

[11] Kindai Univ Hosp, Dept Med Oncol, Osakasayama, Japan

[12] Aichi Canc Ctr Hosp, Thorac Oncol, Nagoya, Aichi, Japan

[13] Univ Calif Irvine, Med, Sch Med, Orange, CA USA

[14] Daiichi Sankyo Inc, Oncol, Basking Ridge, NJ USA

[15] Daiichi Sankyo Co Ltd, Clin Dev, Chuo Ku, Tokyo, Japan

[16] Dauchi Sankyo Europe GmbH, Global Oncol Med Affairs, Munich, Germany

[17] Dana Farber Canc Inst, Lowe Ctr Thorac Oncol, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2354

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1321MO

引用

页数：2

共 50 条

[1] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
Smit, E. F. F.
Li, B. T.
Mazieres, J.
Planchard, D.
Nakagawa, K.
Goto, K.
Paz-Ares, L.
Novello, S.
Yang, J. C-H.
Ahn, M-J.
Liu, G.
O'Byrne, K.
Aregay, M.
Shiga, R.
Saxena, K.
Meinhardt, G.
Janne, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1032 - S1033
[2] Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
Li, B. T.
Smit, E. F. F.
Goto, Y.
Nakagawa, K.
Udagawa, H.
Mazieres, J.
Nagasaka, M.
Bazhenova, L.
Saltos, A. N.
Felip, E.
Pacheco, J. M.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Acharyya, S.
Shahidi, J.
Planchard, D.
Janne, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1323 - S1324
[3] Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
Li, B. T.
Smit, E. F.
Goto, Y.
Nakagawa, K.
Goto, K.
Mazieres, J.
Uprety, D.
Bazhenova, L.
Saltos, A.
Felip, E.
Pacheco, J.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Yan, Q.
Planchard, D.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S995 - S996
[4] Analytical and clinical validation of oncomine Dx target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non-small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL01/02)
Li, Bob T.
De langen, Adrianus
Goto, Koichi
Vitazka, Patrik
Qi, Zhenhao
Ha, Thomas
Marie, Anne
Roth, Velasco
Karnoub, Maha
Feng, Wenqin
Pereira, Kaline
Shiga, Ryota
Khambata-Ford, Shirin
Goto, Yasushi
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[5] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
Goto, K.
Sang-We, K.
Kubo, T.
Goto, Y.
Ahn, M-J.
Planchard, D.
Kim, D-W.
Yang, J. C-H.
Yang, T-Y.
Pereira, K. M. C.
Saxena, K.
Shiga, R.
Cheng, Y.
Aregay, M.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
[6] Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02
Janne, P.
Goto, Y.
Kubo, T.
Ninomiya, K.
Kim, S. -W.
Planchard, D.
Ahn, M. -J.
Smit, E. F.
de Langen, A. J.
Perol, M.
Pons-Tostivint, E.
Novello, S.
Hayashi, H.
Shimizu, J.
Kim, D. -W.
Pereira, K.
Cheng, F. -C.
Taguchi, A.
Cheng, Y.
Goto, K.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S148 - S148
[7] Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial
Smit, E. F.
Felip, E.
Uprety, D.
Nakagawa, K.
Paz-Ares, L.
Pacheco, J.
Li, B. T.
Planchard, D.
Baik, C.
Goto, Y.
Murakami, H.
Saltos, A.
Saxena, K.
Shiga, R.
Cheng, Y.
Yan, Q.
Feng, W.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S994 - S995
[8] A pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) with brain metastases (BMs) from DESTINY-Breast (DB)-01,-02, and-03
Hurvitz, S. A.
Modi, S.
Li, W.
Park, Y. H.
Chung, W.
Kim, S-B.
Cortes, J.
Yamashita, T.
Pedrini, J.
Im, S-A.
Tseng, L-M.
Harbeck, N.
Krop, I.
Curigliano, G.
Mathias, E.
Cathcart, J.
Cagnazzo, A.
Ashfaque, S.
Egorov, A.
Andre, F.
ANNALS OF ONCOLOGY, 2023, 34 : S335 - S336
[9] Trastuzumab deruxtecan (T-DXd) in Asian patients (Pts) with human epidermal growth factor receptor 2 (HER2; ERBB2)mutant (HER2m) metastatic non-small cell lung cancer (mNSCLC): Subgroup analysis of DESTINYeLung02 (DL-02)
Goto, Y.
Goto, K.
Kubo, T.
Ninomiya, K.
Kim, S-W.
Ahn, M-J.
Nakagawa, K.
Hayashi, H.
Shimizu, J.
Kim, D-W.
Yang, J. C-H.
Kuo, C-H. S.
Lee, K. H.
Yang, T-Y.
Pereira, K. M. C.
Taguchi, A.
Ali, A.
Cheng, F-C.
Yonemochi, R.
Janne, P. A.
ANNALS OF ONCOLOGY, 2023, 34 : S1666 - S1667
[10] Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non-small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02.
Janne, Pasi A.
Goto, Yasushi
Kubo, Toshio
Ninomiya, Kiichiro
Kim, Sang-We
Planchard, David
Ahn, Myung-Ju
Smit, Egbert F.
De langen, Adrianus Johannes
Perol, Maurice
Pons-Tostivint, Elvire
Novello, Silvia
Hayashi, Hidetoshi
Shimizu, Junichi
Kim, Dong-Wan
Pereira, Kaline
Cheng, Fu-Chih
Taguchi, Ayumi
Cheng, Yingkai
Goto, Koichi
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →